The Next Era of Obesity Treatment: Unlocking Value Beyond GLP-1s

As obesity rates continue to rise globally, the limitations of current therapies, especially GLP-1 receptor agonists, are becoming increasingly clear. This strategic deep dive explores the most critical shifts redefining obesity treatment. This in-depth analysis explores the evolving landscape beyond first-generation drugs, highlighting novel mechanisms of action, emerging combination therapies and the strategic market shifts driven by a surge in mergers, acquisitions and licensing deals.

Discover how innovation is unlocking new opportunities to address unmet needs and shape the future of obesity care.

1. Current Standard of Care and Market Gaps
   – Rising demand, high costs and side effects hinder long-term use of today’s therapies

2. Next-Gen Therapies: Beyond Weight Loss
   – Emerging MoAs and combo approaches aim to preserve muscle, improve outcomes and reduce discontinuation
3. M&A and Licensing Surge (2023–2025)
   – Over $25B in deals reshape the landscape
   – Shift from M&A to staged licensing
   – Major players defend franchises or race to catch up
   – Growing interest in AI platforms, amylin analogs, CB1 blockers and Asian innovation
4. Strategic Implications
   – Companies must defend GLP-1 backbones while expanding into novel, payer-friendly innovations

Access the Full Analysis to Learn More
Gain insights into key pipeline trends, strategic moves and what’s next in obesity treatment.

Don’t miss out – download your copy of this whitepaper by completing the form.